Mixed symphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation

Lancet

Volumn 353, Issue 9166, 1999, Pages 1755-1759

  Sykes, Megan ^a,b   Preffer, Frederic ^a   McAfee, Steven ^a   Saidman, Susan L ^a   Weymouth, Dina ^a   Andrews, David M ^a   Colby, Christine ^a   Sackstein, Robert ^a   Sachs, David H ^a   Spitzer, Thomas R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; THYMOCYTE ANTIBODY;

ADULT; ALLELE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHIMERA; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HEMATOPOIESIS; HLA MATCHING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPOIESIS; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; ALLOTRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT VS HOST DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0033594552     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11135-2     Document Type: Article

References (23)

1. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050.
2. Verdonck LF, Dekker AW, Lokhorts HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-05.
3. Aizawa S, Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991; 52: 885-89.
4. Sykes M, Sachs DH. Genetic analysis of the anti-leukemic effect of mixed allogeneic bone marrow transplantation. Transplant Proc 1989; 21: 3022-24.
5. Clift RA, Storb R. Histoincompatible bone marrow transplants in humans. Annu Rev Immunol 1987; 5: 43-64.
6. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
7. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391-96.
8. Pelot M, Pearson D, Swenson K, et al. Lymphohematopoietic graft-vs-host reactions can be induced without graph-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloblative conditioning regimen. Biol Blood Marrow Transplant (in press).
9. Preffer FI. Diagnostic cytometry. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic immunopathology, 2 edn. New York: Raven Press, 1993; 725-49.
10. Schwartz DWM, Glock B, Jungl EM, Mayr WR. Strategy to detect chimerism in allogeneic bone marrow transplant recipients by PCR-amplification fragment length polymorphism analysis of microsatellite polymorphisms. Vox Sang 1995; 68: 139-43.
11. Nakao S, Nakasumi T, Chuhjo T, et al. Analysis of late graft failure after allogeneic bone marrow transplantation: detection of residual host cells using amplification of variable number of tandem repeats. Bone Marrow Transplant 1992; 9: 107-11.
12. Lapierre Y, Rigal D, Adam J, et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 1990; 30: 1091-113.
13. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493-502.
14. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-54.
15. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys. Transplantation 1995; 59: 256-62.
16. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-72.
17. Henslee-Downey PJ, Parrish RS, Macdonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 1996; 61: 738-45.
18. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-36.
19. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
20. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24.
21. Giralt S, Gajewski J, Khouri I, et al. Induction of graft-vs-leukemia (GVL) as primary treatment of chronic myelogenous leukemia. Blood 1997; 90: 418A.
22. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-67.
23. Sykes M, Chester CH, Sachs DH. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow. Transplantation 1988; 46: 327-30.